Latest news and press releases about GeneDx Holdings Corp. (WGS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
Price
| Price | $76.27 |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.89 |
| EV / EBITDA | -29.92 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.72% |
| Return on Invested Capital | -14.69% |
| Return on Assets | -22.09% |
| Gross Margin | 68.20% |
| Operating Margin | -13.34% |
| Net Margin | -23.40% |
Related companies: HNGE · IMVT · KYMR · NAMS · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of WGS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks